The Rare Lung Disease Consortium is designed to accelerate the development and application of new knowledge about rare lung disorders, and engage the respective lung disease communities and clinical research centers for treatment trials in rare lung diseases, with the ultimate goal of developing therapies that improve the quality of life for patients by driving the process from pilot studies to FDA approval. The Administrative Core will provide leadership and oversight to the network, building on the institutional support of major clinical research centers with CTSAs and a growing network of RLD clinical care sites. The leadership is comprised of scientists with international recognition for their research on the molecular pathogenesis, diagnosis, and therapy of rare lung disorders. The directors have significant experience in the organization, implementation, and effectiveness of a rare disease clinical research network providing a bridge between clinical investigators and trainees/academic institutions, patient groups, and the general public. The goals of the Administrative Core include coordinating and facilitating communications, organizing infrastructure support, managing policies and documentation, creating and distributing educational materials, and providing fiscal administration of the consortium. Project support includes the organization of a Biostatistics Core and Radiology Core, to provide standardized and expert support to the RLD clinical research studies. The Administrative Core will produce policy and procedure manuals to organize data management between and within the projects, and streamline IRB protocol approval to facilitate multicenter and multinational clinical research studies. The RLDC will collaborate with the RDCRC and the Data Management Coordination Center to collect and transfer data seamlessly between projects. The Administrative Core will also provide guidance on web portal content, and create web content as part of our training program. The RLCN directors and PIs have partnered with patient advocates to create a RLDC Steering Committee that will guide project and program strategies, with advice and oversight of internal and external experts in translational pulmonary research. Coordinated communication, standardized protocols, and administration of multi-center clinical trial sites will create an infrastructure to support significant advances in rare lung disease research.

Public Health Relevance

The Rare Lung Disease Consortium will build a network of academic institutes, clinical! care centers, and patient advocates to create a research and training program that will make advances in the treatment of rare lung diseases. The Administrative Core will provide the leadership, communication strategies and financial administration to run the consortium smoothly, and create policies and procedures for human research protocols and data management that will provide standardized models for research across the network.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Eu, Jerry Pc
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cincinnati Children's Hospital Medical Center
United States
Zip Code
Kropski, Jonathan A; Blackwell, Timothy S (2018) Endoplasmic reticulum stress in the pathogenesis of fibrotic disease. J Clin Invest 128:64-73
Kropski, Jonathan A; Richmond, Bradley W; Gaskill, Christa F et al. (2018) Deregulated angiogenesis in chronic lung diseases: a possible role for lung mesenchymal progenitor cells (2017 Grover Conference Series). Pulm Circ 8:2045893217739807
Gupta, Nishant; Johnson, Simon R; Moss, Joel et al. (2018) Reply to Yanagisawa: Treatment of Pulmonary Lymphangioleiomyomatosis during Pregnancy. Am J Respir Crit Care Med 197:1507-1508
Nevel, Rebekah J; Garnett, Errine T; Schaudies, Deneen A et al. (2018) Growth trajectories and oxygen use in neuroendocrine cell hyperplasia of infancy. Pediatr Pulmonol 53:656-663
Sivley, R Michael; Sheehan, Jonathan H; Kropski, Jonathan A et al. (2018) Three-dimensional spatial analysis of missense variants in RTEL1 identifies pathogenic variants in patients with Familial Interstitial Pneumonia. BMC Bioinformatics 19:18
McCarthy, Cormac; Avetisyan, Ruzan; Carey, Brenna C et al. (2018) Prevalence and healthcare burden of pulmonary alveolar proteinosis. Orphanet J Rare Dis 13:129
McCarthy, Cormac; Lee, Elinor; Bridges, James P et al. (2018) Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis. Nat Commun 9:3127
Gupta, Nishant; Finlay, Geraldine A; Kotloff, Robert M et al. (2017) Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med 196:1337-1348
Papo, Matthias; Diamond, Eli L; Cohen-Aubart, Fleur et al. (2017) High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 130:1007-1013
Gaskill, Christa F; Carrier, Erica J; Kropski, Jonathan A et al. (2017) Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction. J Clin Invest 127:2262-2276

Showing the most recent 10 out of 37 publications